Cool follow-up story from Cravatt lab on covalent targeting of NONO: Structural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO | bioRxiv biorxiv.org/content/10.110…

Another joyful and unparalleled collaboration with the amazing Amy Strom herself during my postdoc at brangwynnelab and Kosmrlj groups -- we developed a novel computational framework to study elastocapillary interactions between condensates and fiber networks (in this case

My lab’s 5-year NIH R01 grant, awarded to study gene therapy for hearing loss, was abruptly terminated. I want to share how this action has been incredibly harmful and disruptive, not just to my lab, but to the scientific process itself. 1/15

Unfortunately, the MLSB Workshop @ NeurIPS (MLSB @ NeurIPS) was rejected this year. Feedback from the deciding committee indicates it was a coin flip decision, with 283 proposals & a number related to “computational biology” More on the future of MLSB soon…

After many months heads down, we at Decade are growing! We are hiring a protein biochemist to help us radically improve cancer treatment. If you like being early and making an impact, we are interested to hear from you! Details here: decade.bio/careers

What if protein function could be triggered only when the right cell cues are present? With SMART, we combine split inteins and logic gating to create a programmable system for cell-specific protein ligation, thus opening new doors for synthetic biology and cell targeting.

New work introducing PCIPs, heterobifunctional chemical inducers of proximity that inhibit DNA repair by recruiting BET proteins to PARP2. Great work uncovering a new form of event-driven pharmacology by Bryce/Eric/Erin and the rest of the team. (1/3) biorxiv.org/content/10.110…

The OpenADMET teams are cranking away. John Chodera (he/him) James Fraser (A$AP J) and I started to formalize the organization and we will have a lot more exciting news in the coming months. For now, here is the hello world blog post: openadmet.org/community/blog…

Depletion of a transcriptional factor ZBTB11 using molecular glue degraders can overcome oxidative-phosphorylation-mediated KRAS inhibitor resistance in pancreatic ductal adenocarcinoma with low acute neurotoxicity nature.com/articles/s4158…

What’s the next PDB? Maybe it’s …the PDB. We just launched diffUSE, a structural biology initiative exploring protein motion & rethinking how we generate and use experimental data. Quick 🧵👇 diffuse.science

We are thrilled to be part of Project Diffuse, building infrastructure for the dynamic future of structural biology. We are co-leading the modeling and encoding efforts of this project, including developing infrastructure to enable AI to learn from experimental data directly.

We mapped the zinc‑finger (ZF) “degrome.” High‑throughput ZF reporters + glutarimide analogs → new CRBN‑recruited degrons and design rules for degraders.

Excited to share my talk hosted by UCTV "A Closer Look at…Genetic Medicine and Artificial Intelligence" discussing RNA, AI and genetic medicine. Together with Komor Lab youtu.be/SSpE8BNOebg?si… via YouTube

1/13 🧵 Today, Bindcraft was published in nature , one of the most famous AIs in biology for designing protein–protein interactions (PPI). In my opinion. Bindcraft represents one of the most important advances in the post–AlphaFold2 era.

In addition to just thinking the work is cool, I'm really proud of the symbiotic relationship teamtomo.org has developed with the Lucas lab over the past year while they built their extensible implementation of 2DTM #OpenSoftwareAcceleratesScience

If you think LLMs are going to solve drug discovery on their own, and wanna sober up this is a pretty good talk to start with. youtube.com/watch?v=OjvftH…

Reed Hastings Disagree vehemently. It misses the unique needs of medicine and STEM fields where high-value contributions aren’t always tied to high compensation. It risks creating barriers for essential talent in those areas.

Five years ago, in October 2020, my institute appointed me to a full professorship. On this occasion, I select 10 representative research papers we published in the past 5 years. It's been an absolute privilege to work with my super-talented, industrious, and fearless students.

Check out our recent collaboration with AbbVie in CellChemicalBiology. We identifed compounds that potently clear tau aggregates. After chemoproteomics and functional studies, we found it covalently targets ER protein P4HB (after metabolic activation). sciencedirect.com/science/articl…

🚀 Excited to share our latest bioRxiv by Christian E. Stieger We unveil TRACERs - Transcriptional Regulation via Active Control of Epigenetic Reprogramming - a new small-molecule-based induced-proximity modality that silences transcription factors by recruiting endogenous